SI-BONE, Inc. Appoints Tony Recupero Chief Commercial Officer

SAN JOSE, Calif., July 5, 2016 /PRNewswire/ -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System^® (iFuse), a triangular-shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that Tony Recupero has joined the executive management team as Chief Commercial Officer and will be responsible for worldwide sales and marketing.  Mr. Recupero brings extensive knowledge of commercialization strategies, developed through a career including more than 30 years in sales, marketing and executive leadership roles in the medical device and diagnostics industry.

Mr. Recupero was previously President of Catalyst Performance Advisors, LLC a consulting firm that developed and implemented comprehensive commercialization strategies for medical device and diagnostic clients.   Mr. Recupero advised clients including NuVasive, LDR, Invuity and OrthoKinematics, among others, on their sales and go-to-market strategies.  Prior to Catalyst, Mr. Recupero was President and CEO of Baxano, Inc., a medical technology company that developed and sold novel product and procedure solutions to treat lumbar spinal stenosis.  During his tenure at Baxano, he grew revenue rapidly to over $9 million while executing a merger with Trans1 to form Baxano Surgical, Inc.  Mr. Recupero was also previously Vice President of Sales at Kyphon, Inc. where he developed and implemented the company's sales and marketing strategy, taking the company from pre-commercialization to over $213 million in revenue in five years.  At Kyphon, Mr. Recupero built a direct sales organization of 225 sales consultants and developed a field based health care specialist education program that is now the industry standard for medical device organizations and established the foundation of growth leading to Kyphon's eventual $4.2 billion acquisition by Medtronic.  Mr. Recupero began his career at United States Surgical Corporation where he spent 10 years in various sales and sales management positions.  Mr. Recupero is a graduate of the Harvard Business School General Manager Program and Kellog Graduate School of Management Sizing and Structuring Sales Organizations program.  He holds a B.A. in Communications from the State University of New York at Albany.

"I am thrilled to welcome Tony to SI-BONE at this exciting time in our company's journey," said Jeffrey Dunn, President and CEO of SI-BONE.  "Tony is a highly accomplished leader with a proven record of driving growth and building long-term commercial platforms, and I am confident that we can leverage his experience and knowledge to accelerate our growth.  Our company is in a very exciting place, with over $20M of fresh growth capital, new products in the pipeline, improving reimbursement in the U.S. and 2-year results from our first randomized controlled trial soon to be published.  I look forward to working with Tony to maximize the opportunity in front of us."

About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is a leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders.  The company develops, manufactures and markets minimally invasive products for the SI joint.  SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010. 

The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, and allow for biological fixation to support long term fusion.  iFuse is the only commercially available SI joint fusion device in the United States with published evidence that demonstrates safety, effectiveness and economic benefits, including three large multicenter prospective studies, two of which are randomized controlled trials (RCTs). Currently, there are more than 40 peer-reviewed publications supporting positive clinical outcomes, safety, biomechanics, and the economic value of iFuse.  It is the only SI joint fusion product with a unique FDA clearance recognizing that clinical studies demonstrate improved pain, patient function and quality of life. 

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.  Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life.  There are potential risks associated with the iFuse Implant System.  It may not be appropriate for all patients and all patients may not benefit.  For information about the risks, visit: www.si-bone.com/risks.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2016 SI-BONE, Inc. All Rights Reserved. 9659.070516

SOURCE SI-BONE, Inc.

Related Links

http://www.si-bone.com